Overview

Safety and Metabolic Study of Highly Active Antiretroviral Therapy (HAART) in Malnourished Children With HIV

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
0
Participant gender:
All
Summary
It is unclear whether children with HIV and severe acute malnutrition can be started on highly active antiretroviral therapy (HAART) safely while they are still malnourished and the manner in which this therapy should start. This study will examine the safety, efficacy, and metabolism of children started on HAART while still severely malnourished.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
Lamivudine
Nevirapine
Zidovudine
Criteria
Inclusion Criteria:

- HIV-infected about to start on HAART for the first time

- 6-59 months old

Exclusion Criteria:

- also being treated for TB

- other chronic illness (e.g., congenital heart disease, cerebral palsy)